The characterization of pharmacological receptors in subcellular preparations has, to date, relied mainly on observations of the binding properties of radioactively labelled ligands. Minimal criteria for receptor-specific binding are that a component of binding should saturate with increasing concentrations of the ligand and that only drugs with the appropriate pharmacological specificity, and at concentrations at which they are pharmacologically active, should displace this binding component. These criteria have provided the basis for the biochemical identification of numerous classes of receptors (see, for example, Cuatrecasas, 1974; Snyder & Bennett, 1976; Fewtrell, 1976) , but in relatively few cases have quantitative correlations between the directly measured binding parameters and pharmacologically derived values been demonstrated.
Difficulties arise in the determination of receptor-binding properties of drugs from dose-response curves in whole tissue, because of the intervention of unknown and probably non-linearly coupled steps between the binding of a drug to a receptor and production of the measured response. The pharmacologically determined parameters have been derived, in general, on the assumption that a drug interacts with a uniform population of binding sites and also, in the case of null methods (Arunlakshana & Schild, 1959; Furchgott, 1966) that equal occupancy of a receptor results in an equal response. These assumptions may not be correct, and thus the pharmacologically determined binding constants could be in error. It is also possible that the binding properties of receptors in tissue homogenates do not reflect the binding properties in the whole tissue. These uncertainties underline the requirement for both determination of the detailed binding properties of the receptor and for the characterization of the processes linking occupancy of the receptor by a drug to the production of the physiological response.
The binding properties of muscarinic receptors in subcellular fractions have been investigated in considerable detail by using a variety of radioactively labelled antagonists (see, for example, Paton & Rang, 1965; Farrow & O'Brien, 1973; Fewtrell & Rang, 1973; Burgen et al., 1974a,b; Beld & Ariens, 1974; Yamamura & Snyder, 1974a,b; Hulme et al., 1976; Wells et al., 1977) and agonists Hulme et al., 1976) . In solutions of a physiological ionic composition, muscarinic antagonists bind to a uniform population of receptor sites on the membrane Wells et al., 1977) , whereas muscarinic agonists exhibit a dispersion in their affinity constants for the same receptor sites. The binding properties of muscarinic receptors in membrane fractions from rat and guinea-pig cortex (Burgen et al., 1974b) , guinea-pig ileum (Burgen et al., 1 9 7 4~; Yamamura & Snyder, 1974b) , neuroblastoma cells (Strange et al., 1977 ; P. G. Strange, N. J. M. Birdsall & A. S. V. Burgen, unpublished work) and in intact smooth muscle (Young, 1974; Taylor ef al., 1975) are the same, suggesting that the heterogeneity in the agonist-binding sites is not an artifact of homogenization. Experiments have shown that the heterogeneity does not result from receptor desensitization or from negatively co-operative interactions between agonist-binding sites Hulme et al., 1976 ). This pattern, in which the binding of antagonists to a receptor is simple, whereas that of agonists is complex and not described by a single affinity constant, also seems to be characteristic of opiate receptors Hulme, 1977) , nicotinic receptors (Michaelson et a/., 1974) and glycine receptors (Young & Snyder, 1973) .
To a first approximation, all the results from binding studies of muscarinic receptors can be fitted to a model in which there are two classes of agonist-binding sites, one having a high affinity (KH) and the other a low affinity (KL) for agonists. This model accords with the fact that antagonist affinity constants, derived from the inhibition of a wide variety of muscarinic receptor-linked responses, are the same for a given antagonist and are independent of the measured response. Indeed, the pharmacologically determined values agree with antagonist affinity constants determined from binding studies (Yamamura & Snyder, 1974a; ; E. C. Hulme, N. J. M. Birdsall &A. S. V. Burgen, unpublished work). The complex agonist-binding properties of muscarinic receptors are similarly reflected in the widely differing concentrations of potent muscarinic agonists that are required to elicit various physiological and biochemical responses. For example, -100nwcarbamoyl-choline produces 50% of the maximum contraction of smooth muscle, whereas a 30-fold higher concentration is required to give 50% of the maximum K+ efflux from preloaded smooth-muscle strips (Burgen & Spero, 1968) .
As the muscarinic contractile response of smooth muscle has been investigated in greatest detail, relationships between agonist dose-response curves for contraction and the directly measured agonist-binding data have been sought. It has been possible to demonstrate a correlation between the absolute values of K, (the reciprocal of the concentration of an agonist which produces 50 % of the maximum contraction of smooth muscle) and KH for a series of muscarinic agonists . This agreement would imply that occupancy of the high-affinity agonist-binding site leads to contraction and that there are no spare receptors for this response. Such a conclusion contradicts the results from a variety of pharmacological experiments with both reversible and irreversible antagonists, which have suggested that potent agonists, e.g. acetylcholine or carbamoylcholine, are capable of eliciting a maximum contractile response at low receptor occupancies (Stephenson, 1956; Rang, 1966; Furchgott & Burstzyn, 1967; Burgen & Spero, 1968) , whereas partial agonists do not produce the maximum response even at 100% occupancy. From an analysis of these experiments it has been possible to derive values of the pharmacological agonist affinity constant, K, of a given agonist and its efficacy, e, which is approximately equal to K,/K. Comparison of the binding data with these derived values shows a correlation between Kand KL, and hence between e and KH/KL. Therefore, if one allows the existence of spare receptors, it is possible to equate occupancy of the low-affinity agonist-binding site with the production of the contractile response. However, this assignment does not explain either the existence of the high-affinity binding site or the relationships between KH/KL and e and between KH and K,.
The problems associated with the analysis of the contractile response in terms of the agonist-binding properties of the receptor would appear to result from the chain of largely unknown steps linking receptor occupancy to the response. It is therefore important to search for muscarinic receptor-linked responses which are directly and linearly coupled to the initial interaction of the agonist with the receptor.
Phosphatidylinositol breakdown and subsequent resynthesis have been shown to be enhanced by muscarinic agonists in a number of tissues known to contain muscarinic receptors (Hokin & Sherwin, 1957; Michell et af., 1976) . The only published dose-response curve, that of carbamoylcholine-stimulated incorporation of 32Pi into phosphatidylinositol in the smooth muscle of the ileum, closely parallels the carbacholbinding curve and suggests that the phosphatidylinositol response may be linearly coupled t o both the high-and low-affinity agonist-binding sites . However, the partial agonist pilocarpine produces the same maximum response as the potent agonist carbachol and thus this hypothesis is difficult t o reconcile with the differences in efficacy found in smooth muscle for these two agonists. The muscarinic-agonist-induced cyclic G M P response in neuroblastoma cells (Matsuzawa & Nirenberg, 1975 Burgen, unpublished work) appears t o be linked t o occupancy of the low-affinity site and there is a possible correlation with efficacy in that the partial agonist pilocarpine does not produce a detectable response (Strange et al., 1977) .
Although it has been impossible t o demonstrate correlations between the agonist-binding data in vitro and agonist dose-response curves for physiological responses, there is a t the present time n o unique physical interpretation of these correlations. A successful resolution of these conflicts requires both a reexamination of the assumptions underlying the derivation of the pharmacological-agonist affinity constants and a detailed investigation of the molecular events which occur after the formation of the agonist-receptor complex.
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